What we know about the new Covid-19-linked illness in children

Doctors are seeing a spike in cases of an illness similar to Kawasaki disease — especially in areas with recent or ongoing Covid-19 outbreaks. | Getty Images

A rare, Kawasaki-like disease is striking kids who have coronavirus antibodies.

Doctors in at least 20 US states have seen kids who have fallen sick with a rare inflammatory illness similar to a condition known as Kawasaki disease. Symptoms include fever and inflammation and can affect organs, including the heart. The majority of the children have tested positive for Covid-19 or antibodies to the virus, and three have died.

More from CDC briefing on Kawasaki-like condition MIS-C: 1) Now in 20 states 2) Symptoms include stomach pain, vomiting, rash, fever 3) Respiratory symptoms rare 4) MIS-C requires immediate attention and likely hospitalization 5) No underlying conditions predispose kids to MIS-C.

— Matt McCarthy (@DrMattMcCarthy) May 20, 2020

New York City alone has reported 147 cases of the pediatric inflammatory syndrome so far, with about a third of cases occurring in children younger than 5, and about half between the ages of 5 and 14.

Clusters of the illness have also popped up in other Covid-19 hot spots, including California, New Jersey, and Illinois. The potentially deadly syndrome is also affecting a small number of children in other countries, including the UK, Spain, and now Italy.

A peer-reviewed study out of Italy, published May 13 in The Lancet, details the cases of 10 children who presented with this condition during the Covid-19 outbreak there. Eight of the 10 children tested positive for the SARS-CoV-2 virus that causes Covid-19 in an antibody test.

“Our study provides the first clear evidence of a link between SARS-CoV-2 infection and this inflammatory condition, and we hope it will help doctors around the world as we try to get to grips with this unknown virus,” said Lorenzo D’Antiga, lead author of the study from the Hospital Papa Giovanni XXIII in Bergamo, Italy, in a statement.

Lauren Henderson, an attending physician at Boston Children’s Hospital and assistant professor of pediatrics at Harvard Medical School, called it, “a very important study.”

This work — and other ongoing research — aims to decipher what about the new coronavirus might trigger this serious condition, how to treat it, and how it might help us understand the virus itself better.

What is Kawasaki disease?

Originally observed in Japan in the 1960s, Kawasaki disease is triggered by high levels of inflammation and can lead to trouble in the blood vessels and heart, among other places in the body, and occasionally prompt toxic shock syndrome and death.

Traditional symptoms can include a persistent high fever, skin rash, pinkeye, swollen hands and feet, and cracked lips. There is no test for the condition, so doctors rely on these signs and other laboratory measurements to determine if a child likely has it. (It is primarily a pediatric condition, although adults can get it too.)

When Kawasaki disease is identified and addressed promptly, it is usually treatable. Doctors typically administer antibody treatment and sometimes steroids and other medications, such as aspirin.

And, fortunately, Kawasaki disease is usually very rare, normally striking only about 21 children under the age of 5 per 100,000 in the US each year.

But now doctors are seeing a spike in cases of a similar illness — especially in areas with recent or ongoing Covid-19 outbreaks. And early reports suggest these patients have more severe illnesses than the average case.

How the new cases seem to be different

The authors of the new study in The Lancet are calling the illness the “Kawasaki-like disease,” acknowledging that they are very early in understanding it — and how it is related to Covid-19. Experts in the US are calling the condition “multisystem inflammatory syndrome in children”; the Centers for Disease Control and Prevention issued a working definition of the condition and recommendations to clinicians May 14.

In the 10 patients in Italy, doctors found antibodies to the virus in eight of the children — three of whom also had a current infection. The authors also noted they suspect that at least one of the other two might have had false negative antibody results due to testing issues.

As part of the analysis, the authors compared the recent pandemic cases with the records of the 19 patients with the condition that they treated over the past five years. Although the study was small, they found some key and worrisome patterns that distinguished the pandemic patients from others with Kawasaki disease in years past.

One key difference is “the patients with [this illness] and Covid-19 were sicker and had different lab test abnormalities” than those seen before the new coronavirus reached the area, Henderson told Vox. “This tells us that the children with Kawasaki disease features and Covid-19 might not be exactly like other more classical Kawasaki disease patients.”

For example, the researchers found that typically about 10 percent of their previous Kawasaki patients had heart issues (as detected by abnormal echocardiograms), whereas 60 percent of the pandemic cases did.

The newer patients were also more likely to have a severe inflammatory response known as mitochondrial activation syndrome, which, as the authors of the paper note, “is a form of cytokine storm.” ( Cytokine storms are extreme immune reactions in the body, which have been fingered as culprits as much of the damage seen in critical adult Covid-19 patients.)

The doctors also found they needed to treat the recent patients with more medications to help them recover.

The children diagnosed during the outbreak also tended to be older (a mean age of 7.5 years) than kids they usually treated for the illness (who had a mean age of 3 years). In fact, Kawasaki disease is usually tracked for children younger than 5. But in this new group, the patients ranged in age from 5.5 to 16 years old.

Treatment, however, seems to work similarly for both conditions. A new report, published in the American Heart Association journal Circulation, shows that patients with the new illness seem to be responding well to the traditional treatments for Kawasaki disease: antibody therapy, sometimes combined with steroids.

The researchers looked at the treatment history for 35 pediatric patients (ages 2-16) admitted to the ICU with symptoms of the inflammatory conditions in France and Switzerland during the Covid-19 pandemic. After being given the standard treatment, all of the children described in the report survived — and “the majority of patients recovered within a few days,” the researchers noted in the paper.

How is this inflammatory disease linked to Covid-19?

Despite having studied Kawasaki disease for decades, researchers still don’t know exactly what triggers it. Even before Covid-19, a working hypothesis has been that a runaway immune response — possibly combined with a genetic predisposition — brought it on. Previous research had even looked for evidence of other coronaviruses in Kawasaki patients, but overall the evidence was generally only weakly correlated.

The new patterns emerging in places with severe outbreaks of Covid-19, however, are significant. And even though the Italian study was small, the researchers noted that the rate of Kawasaki-like cases at their hospital in the outbreak center of Bergamo had jumped 30 times to their usual rate in the month they studied.

The timing is also interesting to researchers. “If you look at the curves, Covid-19 has plateaued, but there’s an exponential rise in this secondary type of shock syndrome,” Jane Newburger, a cardiologist at Boston Children’s Hospital, said in a release. “It is even possible that the antibodies that children are making to SARS-CoV-2 are creating an immune reaction in the body. Nobody knows.”

According to Henderson, “It will be very important for other studies to replicate these results at other centers. It is even more important for doctors to enroll children in prospective studies to get the best information possible about this disease.”

Researchers are also interested in how this could clarify some outstanding questions about the virus itself — and how we might fight it in the broader population.

For example, “if this is an antibody-mediated phenomenon, there might be implications for vaccine studies, and this might also explain why some children become very ill with Covid-19, while the majority are unaffected or asymptomatic,” write Russell Viner, president of the Royal College of Pediatrics and Child Health, and Elizabeth Whittaker, secretary of the British Pediatric Allergy Immunity and Infection Group, in a related commentary in The Lancet.

So far, at least three children have been reported to have died from this inflammatory illness in New York state. All 10 children in the Italian study have since recovered enough to be released from the hospital, although they were still taking medicine at the time of publication. And the researchers say they are scheduled to all have ECGs to check their heart function in the next couple of months.

Still, the researchers argue that the findings reveal a key potential consequence of Covid-19 infections in children.

“The association between SARS-CoV-2 and Kawasaki-like disease should be taken into account when it comes to considering social reintegration policies for the pediatric population,” the Lancet authors write.

In a Senate committee hearing Tuesday, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, also remarked that there are many unknowns with Covid-19, “particularly when it comes to children ... We really have to be very careful because the more and more we learn, we’re seeing what this virus can do.”

As Henderson told Vox, “As in any infection, it is important for parents to seek care with their pediatrician if their child has high fevers, new rash, significant abdominal pain, persistent vomiting, persistent diarrhea, or any other concerning symptom.”

But she and other doctors underscore that despite the increased incidence of the pediatric syndrome, it is still quite rare, “probably affecting no more than one in 1,000 children exposed to SARS-CoV-2,” the Lancet authors write. Henderson added, “most children with Covid-19 do very well and have mild symptoms.”

Support Vox’s explanatory journalism

Every day at Vox, we aim to answer your most important questions and provide you, and our audience around the world, with information that has the power to save lives. Our mission has never been more vital than it is in this moment: to empower you through understanding. Vox’s work is reaching more people than ever, but our distinctive brand of explanatory journalism takes resources — particularly during a pandemic and an economic downturn. Your financial contribution will not constitute a donation, but it will enable our staff to continue to offer free articles, videos, and podcasts at the quality and volume that this moment requires. Please consider making a contribution to Vox today.